## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 8.7% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($55.00)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. After shakeup under new CEO, drugmaker BioMarin turns its cash on a big deal**
- Source: The Business Journals | 20251220T140910 | Somewhat-Bullish | Relevance: 100%
- Under its new CEO Alexander Hardy, BioMarin Pharmaceutical is embarking on a significant acquisition, signaling a shift in its corporate strategy. The drugmaker plans to acquire Amicus Therapeutics for $4.8 billion, marking a departure from its predecessor's approach. This move is highlighted as a key development for the Bay Area drugmaker.

**2. BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus**
- Source: Finviz | 20251220T140910 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) surged 17.71% after announcing a definitive agreement to acquire Amicus Therapeutics for nearly $5 billion. This all-cash transaction, priced at $14.50 per share, aims to expand BioMarin's commercial portfolio with treatments for Fabry and Pompe diseases, expecting to increase long-term revenue growth and be accretive to Non-GAAP Diluted EPS.

**3. BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $60.00 Price Target at HC Wainwright**
- Source: MarketBeat | 20251222T141016 | Neutral | Relevance: 100%
- HC Wainwright adjusted its price target for BioMarin Pharmaceutical (NASDAQ:BMRN) from $55.00 to $60.00, maintaining a "neutral" rating despite the company missing its recent quarterly EPS and revenue estimates. While the new target suggests a slight downside, the consensus among 25 analysts is a "Moderate Buy" with an average price target of $88.83, significantly higher than the current share price. BioMarin also provided a positive FY2025 EPS guidance, surpassing analyst projections.

**4. BioMarin stock price target raised to $60 from $55 at H.C. Wainwright**
- Source: Investing.com | 20251222T131015 | Somewhat-Bullish | Relevance: 100%
- H.C. Wainwright has increased its price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $60 from $55, while maintaining a Neutral rating, following BioMarin's acquisition of Amicus. The firm views the acquisition as a strategic move to secure long-term cash flow durability, despite the peak sales payoff for the acquired products not being expected until the 2030s. BioMarin's management projects over $1 billion in peak revenue for each of Amicus' products, Galafold and Pombiliti+Opfolda, which contributed to the revised price target.

**5. BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus**
- Source: Yahoo Finance | 20251220T131300 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw its stock jump 17.7% after announcing a definitive agreement to acquire Amicus Therapeutics for nearly $5 billion. The all-cash transaction, valued at $14.50 per share, aims to enhance BioMarin's commercial portfolio with treatments for Fabry disease and Pompe disease, significantly boosting expected revenue growth through 2030.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | HC Wainwright & | $60 | $55 | +9% |
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | HC Wainwright & | main | Neutral |
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +10.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.61 indicates undervaluation relative to growth. Forward P/E 11.2x attractive for 49% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.4B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.61 |
| Forward P/E | 11.2 |
| Current P/E | 16.6 |
| YoY Growth | 48.5% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -1.4% to 8.7% (+10.1% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (8.7% > 6.0%), caution on chasing. MRS_5 at 6.0% confirms short-term momentum alignment. Outperforming sector by 8.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.58), confirming momentum. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 8.65% (CS: 98) | Strong |
| RSI_14 | 65.4 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 1.089x | Above |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $59.28
- **Stop Loss:** $55.00 (7.2% risk)
- **Target:** $63.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 280
- **Position Value:** $16,598.40
- **Portfolio %:** 16.60%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.34 | $0.12 | -64.3% |
| 2025Q2 | $1.03 | $1.44 | +39.4% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*